NASDAQ:HROW Harrow (HROW) Stock Price, News & Analysis → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free HROW Stock Alerts $11.60 +1.31 (+12.73%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$10.20▼$11.6150-Day Range$10.00▼$13.5152-Week Range$7.60▼$27.80Volume1.13 million shsAverage Volume397,741 shsMarket Capitalization$410.41 millionP/E RatioN/ADividend YieldN/APrice Target$28.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Harrow alerts: Email Address Harrow MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside142.5% Upside$28.13 Price TargetShort InterestBearish15.55% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 5 Articles This WeekInsider TradingAcquiring Shares$1.86 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.39) to $0.69 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.72 out of 5 starsMedical Sector441st out of 925 stocksPharmaceutical Preparations Industry203rd out of 430 stocks 3.5 Analyst's Opinion Consensus RatingHarrow has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHarrow has only been the subject of 2 research reports in the past 90 days.Read more about Harrow's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.55% of the outstanding shares of Harrow have been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Harrow has recently decreased by 7.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHarrow does not currently pay a dividend.Dividend GrowthHarrow does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HROW. Previous Next 2.0 News and Social Media Coverage News SentimentHarrow has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Harrow this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Harrow to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harrow insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,864,011.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.60% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harrow's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Harrow are expected to grow in the coming year, from ($0.39) to $0.69 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow is -15.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow is -15.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow has a P/B Ratio of 5.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harrow's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Harrow Stock (NASDAQ:HROW)Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Read More HROW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HROW Stock News HeadlinesApril 26, 2024 | insidertrades.comHarrow Health, Inc. (NASDAQ:HROW) Major Shareholder Purchases $199,400.00 in StockApril 25, 2024 | insidertrades.comOpaleye Management Inc. Purchases 11,715 Shares of Harrow Health, Inc. (NASDAQ:HROW) StockMay 11, 2024 | Colonial Metals (Ad)Collapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. For one main reason.April 21, 2024 | insidertrades.comOpaleye Management Inc. Acquires 29,400 Shares of Harrow Health, Inc. (NASDAQ:HROW) StockMay 11, 2024 | americanbankingnews.comHarrow (HROW) Scheduled to Post Earnings on MondayMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rapid Micro Biosystems (RPID), COMPASS Pathways (CMPS) and Harrow Health (HROW)May 2, 2024 | seekingalpha.comHarrow: Merits A Buy On Sales PotentialMay 2, 2024 | seekingalpha.comHarrow: The Bull Thesis Is On Track, But Short-Term Challenges LoomMay 11, 2024 | Colonial Metals (Ad)Collapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. For one main reason.April 25, 2024 | businesswire.comHarrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024April 20, 2024 | finance.yahoo.comHarrow, Inc. (HROW)April 3, 2024 | bizjournals.comMelt Pharmaceuticals raises $24 million for drug developmentApril 2, 2024 | finance.yahoo.comMelt Pharmaceuticals Closes $24 Million Series B Preferred Stock FinancingMarch 21, 2024 | finance.yahoo.comHarrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | investorplace.comWhy Is Harrow (HROW) Stock Up 5% Today?March 20, 2024 | msn.comHarrow Health Non-GAAP EPS of -$0.20 misses by $0.15, revenue of $36.36M misses by $1.5MMarch 19, 2024 | investorplace.comHROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q4 2023March 19, 2024 | finance.yahoo.comHarrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023March 19, 2024 | businesswire.comHarrow Announces Fourth Quarter and Year-End 2023 Financial ResultsMarch 18, 2024 | benzinga.comEarnings Preview: Harrow HealthMarch 13, 2024 | finance.yahoo.comHarrow (HROW) Fell on Lowering the GuidanceMarch 5, 2024 | finance.yahoo.comHarrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024February 29, 2024 | finance.yahoo.comHere’s How Harrow (HROW) Weighed on SRK Capital’s PerformanceFebruary 15, 2024 | businesswire.comHarrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical ProductsJanuary 11, 2024 | msn.comHarrow says dry eye drug Vevye now available in USJanuary 11, 2024 | finance.yahoo.comHarrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye DiseaseJanuary 3, 2024 | bizjournals.comHarrow Inc. partners with technology companies for dry eye prescription VevyeSee More Headlines Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today5/11/2024Next Earnings (Confirmed)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HROW Previous SymbolNASDAQ:HROW CUSIPN/A CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees182Year FoundedN/APrice Target and Rating Average Stock Price Target$28.13 High Stock Price Target$34.40 Low Stock Price Target$24.00 Potential Upside/Downside+142.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,410,000.00 Net Margins-18.75% Pretax Margin-18.21% Return on Equity-29.48% Return on Assets-5.37% Debt Debt-to-Equity Ratio2.60 Current Ratio2.83 Quick Ratio2.61 Sales & Book Value Annual Sales$130.19 million Price / Sales3.15 Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book5.77Miscellaneous Outstanding Shares35,380,000Free Float30,570,000Market Cap$410.41 million OptionableOptionable Beta0.58 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Mark L. Baum J.D. (Age 49)CEO & Chairman Comp: $1.07MMr. Andrew R. Boll C.F.A. (Age 40)C.M.A., CFA, CMA, CFO & Corp. Sec. Comp: $716.73kDr. Robert J. Kammer D.D.S. (Age 73)Special Advisor Comp: $91.88kMr. John P. Saharek MBA (Age 62)Chief Commercial Officer Comp: $621.92kJamie WebbDirector of Communications & Investor RelationsDr. Dennis E Saadeh Pharm.D.Chief of Formulation StrategyMr. Andrew LivingstonChief Innovation OfficerMs. Kim BarrattChief Talent OfficerMore ExecutivesKey CompetitorsErascaNASDAQ:ERASMereo BioPharma GroupNASDAQ:MREORani TherapeuticsNASDAQ:RANIADC TherapeuticsNYSE:ADCTAmarinNASDAQ:AMRNView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 21,253 shares on 5/10/2024Ownership: 5.172%Swiss National BankSold 3,400 shares on 5/7/2024Ownership: 0.166%BNP Paribas Financial MarketsBought 1,912 shares on 5/1/2024Ownership: 0.048%China Universal Asset Management Co. Ltd.Bought 2,682 shares on 4/29/2024Ownership: 0.019%Opaleye Management Inc.Bought 20,000 shares on 4/25/2024Total: $199,400.00 ($9.97/share)View All Insider TransactionsView All Institutional Transactions HROW Stock Analysis - Frequently Asked Questions Should I buy or sell Harrow stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harrow in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HROW shares. View HROW analyst ratings or view top-rated stocks. What is Harrow's stock price target for 2024? 2 equities research analysts have issued twelve-month target prices for Harrow's shares. Their HROW share price targets range from $24.00 to $34.40. On average, they anticipate the company's stock price to reach $28.13 in the next year. This suggests a possible upside of 142.5% from the stock's current price. View analysts price targets for HROW or view top-rated stocks among Wall Street analysts. How have HROW shares performed in 2024? Harrow's stock was trading at $11.20 at the beginning of the year. Since then, HROW stock has increased by 3.6% and is now trading at $11.60. View the best growth stocks for 2024 here. When is Harrow's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our HROW earnings forecast. How can I listen to Harrow's earnings call? Harrow will be holding an earnings conference call on Tuesday, May 14th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "3093849". How were Harrow's earnings last quarter? Harrow, Inc. (NASDAQ:HROW) issued its earnings results on Tuesday, March, 19th. The company reported ($0.27) EPS for the quarter. The firm had revenue of $36.36 million for the quarter, compared to analyst estimates of $37.65 million. Harrow had a negative net margin of 18.75% and a negative trailing twelve-month return on equity of 29.48%. What ETF holds Harrow's stock? Jacob Forward ETF holds 10,538 shares of HROW stock, representing 3.95% of its portfolio. What guidance has Harrow issued on next quarter's earnings? Harrow updated its FY 2024 earnings guidance on Friday, March, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $180.0 million-, compared to the consensus revenue estimate of $188.7 million. What other stocks do shareholders of Harrow own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO). Who are Harrow's major shareholders? Harrow's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.17%), Wasatch Advisors LP (1.10%), Rice Hall James & Associates LLC (0.69%), Woodmont Investment Counsel LLC (0.60%), Equitable Trust Co. (0.24%) and Swiss National Bank (0.17%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Martin A Makary, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom. View institutional ownership trends. How do I buy shares of Harrow? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HROW) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetryThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
